SCHEMBL15034148

SCHEMBL15034148

CC(C)Oc1cccc(C(=O)N2CCN(C(=O)c3ncn(-c4ccccc4)n3)C(C)(C)C2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HTT P42858 3/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 7/20 0.40
TP53 P04637 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
CFTR P13569 1/20 0.39
KDM4E B2RXH2 2/20 0.38
RECQL P46063 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
ABL1 P00519 2/20 0.37
BCR P11274 2/20 0.37
KCNK3 O14649 1/20 0.37
KCNK9 Q9NPC2 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
PARP14 Q460N5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034139 0.91 ALDH1A1 (0.47) MEN1KMT2AMAPTTP53SMN1; SMN2
SCHEMBL15034142 0.91 SLC16A3 (0.40) MEN1KMT2AHTTGAAMAPT
SCHEMBL15020047 0.88 HPGD (0.41) MEN1KMT2AMAPTTP53SMN1; SMN2
SCHEMBL15034134 0.87 CFTR (0.44) MAPTTP53SMN1; SMN2POLBCFTR
SCHEMBL15034152 0.87 MAPT (0.39) MEN1KMT2AMAPTTP53SMN1; SMN2
SCHEMBL15034138 0.86 HPGD (0.44) HTTMAPTTP53SMN1; SMN2POLB
SCHEMBL15034136 0.86 CFTR (0.40) MAPTTP53SMN1; SMN2POLBCFTR
SCHEMBL15020006 0.85 ALDH1A1 (0.44) MEN1KMT2AHTTMAPTTP53
SCHEMBL15034131 0.85 CYP3A4 (0.48) MEN1KMT2AHTTSMN1; SMN2ABL1
SCHEMBL15034147 0.84 HPGD (0.41) MEN1KMT2AHTTMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 MEN1 4775/4885KMT2A 1410/4885HTT 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.